

# Mölnlycke® Epidermolysis Bullosa cutting guide



# The lightest touch

EB is a rare, inherited group of skin disorders characterised by fragile skin and the formation of blisters after minor trauma or spontaneously, mainly on the hands and feet. For some patients, this means a life overshadowed by pain, distress, endless dressing changes and treatments.

The combination of fragile skin and frequent dressing changes means that atraumatic dressings are recommended to prevent further pain, damage or bleeding.

Silicone-based dressings are easier to apply and remove than traditional dressings. They also help protect the wound and periwound skin, creating a favourable environment for wound healing.

Mölnlycke created Safetac® – the original soft silicone adhesion – specifically to reduce pain and suffering during dressing change.


The recommended solutions for managing EB, as set out in the international consensus best practice for skin and wound care in EB, include several Mölnlycke products, all containing Safetac technology:

**Mepilex®** | **Mepilex® Lite** | **Mepilex® Transfer**



## Ear

e.g. 7.5x8.5cm




## Application



## Elbow

e.g. 10x12cm



## Application



## Between toes

e.g. 10x12cm




## Application



## Heel

e.g. 10x12cm




## Application



## Tip of toe

e.g. 7.5x8.5cm




## Application



## Hand

e.g. 10x12cm




## Application



## Around tubes

e.g. 7.5x8.5cm




## Application



# General all purpose for younger patients

e.g. 10x12cm



See all video tutorials at:  
[https://qr.molnlycke.com/  
p6bk0j](https://qr.molnlycke.com/p6bk0j)

Find out more at [www.molnlycke.co.uk](http://www.molnlycke.co.uk)

Molnlycke Health Care Limited, Unity House, Medlock Street, Oldham, Lancashire, OL1 3HS. Phone + 44 (0) 161 621 3900.  
The Molnlycke, Mepilex and Safetac trademarks, names and logotypes are registered globally to one or more of the  
Molnlycke Health Care group of companies. © 2025 Molnlycke Health Care AB. All rights reserved. UKWC1382

